105 related articles for article (PubMed ID: 2387656)
1. Current French system of post-marketing drug surveillance.
Albengres E; Gauthier F; Tillement JP
Int J Clin Pharmacol Ther Toxicol; 1990 Jul; 28(7):312-4. PubMed ID: 2387656
[TBL] [Abstract][Full Text] [Related]
2. Features of the French postmarketing drug surveillance system. Application to cutaneous effects of nonsteroidal antiinflammatory drugs.
Albengres E
J Rheumatol Suppl; 1988 Oct; 17():20-3. PubMed ID: 3204616
[TBL] [Abstract][Full Text] [Related]
3. [Organization and results of drug vigilance in France].
Bégaud B; Chaslerie A; Haramburu F
Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
[TBL] [Abstract][Full Text] [Related]
4. [French system of drug surveillance].
Imbs JL; Castot A; Begaud B; Larousse C; Blayac JP; Alexandre JM
Bull Acad Natl Med; 1998; 182(7):1383-91; discussion 1392-3. PubMed ID: 9916332
[TBL] [Abstract][Full Text] [Related]
5. Decision support methods for the detection of adverse events in post-marketing data.
Hauben M; Bate A
Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
[TBL] [Abstract][Full Text] [Related]
6. How to anticipate the assessment of the public health benefit of new medicines?
Massol J; Puech A; Boissel JP;
Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
[TBL] [Abstract][Full Text] [Related]
7. [Computerized detection of new adverse effects in drug surveillance. A proposal for the periodic use of the French data bank].
Pham E; Ventre JJ; Saddier P; Descotes J; Evreux JC
Therapie; 1988 May; 43(3):235-7. PubMed ID: 3420571
[No Abstract] [Full Text] [Related]
8. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France].
Bégaud B; Evreux JC; Jouglard J; Lagier G
Therapie; 1985; 40(2):111-8. PubMed ID: 4002188
[No Abstract] [Full Text] [Related]
9. [Drug by drug imputation of adverse effects in drug monitoring. Attempted comparison of different methods].
Lagier G; Vincens M; Lefebure B; Frelon JH
Therapie; 1983; 38(3):295-302. PubMed ID: 6612666
[No Abstract] [Full Text] [Related]
10. [Drug surveillance and adverse reactions to drugs. The literature and importance of historical data].
Mariani L; Minora T; Ventresca GP
Clin Ter; 1996 Dec; 147(12):653-72. PubMed ID: 9296925
[TBL] [Abstract][Full Text] [Related]
11. [Mandatory report of adverse effects of drugs: has the order modified the spontaneous notification?].
Haramburu F; Pere JC; Begaud B; Albin H
Therapie; 1988; 43(6):493-6. PubMed ID: 3227516
[No Abstract] [Full Text] [Related]
12. Advantages of adverse-effect reporting by patients.
Prescrire Int; 2011 Mar; 20(114):70. PubMed ID: 21648228
[No Abstract] [Full Text] [Related]
13. [Is imputation in drug surveillance reliable?].
Girard M
Therapie; 1984; 39(3):291-6. PubMed ID: 6463954
[No Abstract] [Full Text] [Related]
14. Emergency department visits for outpatient adverse drug events: demonstration for a national surveillance system.
Budnitz DS; Pollock DA; Mendelsohn AB; Weidenbach KN; McDonald AK; Annest JL
Ann Emerg Med; 2005 Feb; 45(2):197-206. PubMed ID: 15671977
[TBL] [Abstract][Full Text] [Related]
15. Statewide test of a new postmarketing drug surveillance system.
Fisher S; Bryant SG; Solovitz BL; Kluge RM
Tex Med; 1987 Aug; 83(8):59-62. PubMed ID: 3660262
[No Abstract] [Full Text] [Related]
16. [Official systems of pharmacovigilance in France and in Spain. Comparison of spontaneous reporting in two regional centers: Pays Basque and Bordeaux].
Aguirre C; Haramburu F
Therapie; 1995; 50(6):563-9. PubMed ID: 8745957
[TBL] [Abstract][Full Text] [Related]
17. An underrecognized challenge in evaluating postmarketing drug safety.
Roden DM
Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
[No Abstract] [Full Text] [Related]
18. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
Fleuranceau-Morel P
Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
[TBL] [Abstract][Full Text] [Related]
19. [Drug monitoring].
Royer RJ
Bull Soc Ophtalmol Fr; 1985 Nov; Spec No():11-30. PubMed ID: 4064240
[No Abstract] [Full Text] [Related]
20. The US drug safety system: role of the pharmaceutical industry.
Gibson BR; Suh R; Tilson H
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
